Robert S Venick1, Douglas G Farmer2, Jose R Soto2, Jorge Vargas3, Hasan Yersiz2, Fady M Kaldas2, Vatche G Agopian2, Jonathan R Hiatt2, Sue V McDiarmid4, Ronald W Busuttil2. 1. Department of Pediatrics, David Geffen School of Medicine at UCLA, University of California, Los Angeles, Los Angeles, CA; Department of Surgery, David Geffen School of Medicine at UCLA, University of California, Los Angeles, Los Angeles, CA. Electronic address: Rvenick@mednet.ucla.edu. 2. Department of Surgery, David Geffen School of Medicine at UCLA, University of California, Los Angeles, Los Angeles, CA. 3. Department of Pediatrics, David Geffen School of Medicine at UCLA, University of California, Los Angeles, Los Angeles, CA. 4. Department of Pediatrics, David Geffen School of Medicine at UCLA, University of California, Los Angeles, Los Angeles, CA; Department of Surgery, David Geffen School of Medicine at UCLA, University of California, Los Angeles, Los Angeles, CA.
Abstract
BACKGROUND: Pediatric liver transplantation (pLTx) has been the standard of care for children with liver failure since the 1980s. This study examined the world's largest single-center experience and aimed to identify unique preoperative predictors of early graft and patient survival for primary transplantation (1°-pLTx) and retransplantation (Re-pLTx). STUDY DESIGN: We conducted an IRB-approved, retrospective study of all consecutive, isolated pLTx patients 18 years of age or younger. Twenty-eight demographic, laboratory, and perioperative variables were analyzed as potential outcome predictors. Univariate and multivariate analyses were performed using log-rank test and Cox's proportional hazards model. RESULTS: There were 806 children who received 1,016 isolated pLTx between February1984 and June 2017. Median follow-up was 12 years. Leading indications for pLTx were cholestatic liver disease (40%), re-pLTx (21%), and fulminant hepatic failure (14%). Seventy-three percent received cadaveric whole grafts. Overall graft and patient survival rates at 0.5, 1, 5, 10, and 20 years were: 76%, 73%, 67%, 63%, 53%, and 87%, 86%, 81%, 78%, 69%, respectively. Relative to 1°-pLTx, re-pLTx recipients were significantly older, larger, with worse renal function, and more likely to be awaiting pLTx in an ICU. Independent significant predictors of graft survival for 1°-pLTx included weight, transplantation era, and renal replacement therapy; for re-pLTx, warm ischemia time and time between 1°-pLTx and re-pLTx. Independent significant predictors of patient survival were renal function, mechanical ventilation, and etiology of liver disease. CONCLUSIONS: This is the largest reported single-center experience of pLTx with substantial follow-up time and a large re-pLTx experience. Important transplant predictors of graft survival include weight, renal function, modern era, warm ischemia time, and time between primary transplantation and re-pLTx. Renal function, mechanical ventilation, and underlying cause of liver disease affect patient survival. Awareness of these factors can help in the decision making for children requiring pLTx.
BACKGROUND: Pediatric liver transplantation (pLTx) has been the standard of care for children with liver failure since the 1980s. This study examined the world's largest single-center experience and aimed to identify unique preoperative predictors of early graft and patient survival for primary transplantation (1°-pLTx) and retransplantation (Re-pLTx). STUDY DESIGN: We conducted an IRB-approved, retrospective study of all consecutive, isolated pLTx patients 18 years of age or younger. Twenty-eight demographic, laboratory, and perioperative variables were analyzed as potential outcome predictors. Univariate and multivariate analyses were performed using log-rank test and Cox's proportional hazards model. RESULTS: There were 806 children who received 1,016 isolated pLTx between February1984 and June 2017. Median follow-up was 12 years. Leading indications for pLTx were cholestatic liver disease (40%), re-pLTx (21%), and fulminant hepatic failure (14%). Seventy-three percent received cadaveric whole grafts. Overall graft and patient survival rates at 0.5, 1, 5, 10, and 20 years were: 76%, 73%, 67%, 63%, 53%, and 87%, 86%, 81%, 78%, 69%, respectively. Relative to 1°-pLTx, re-pLTx recipients were significantly older, larger, with worse renal function, and more likely to be awaiting pLTx in an ICU. Independent significant predictors of graft survival for 1°-pLTx included weight, transplantation era, and renal replacement therapy; for re-pLTx, warm ischemia time and time between 1°-pLTx and re-pLTx. Independent significant predictors of patient survival were renal function, mechanical ventilation, and etiology of liver disease. CONCLUSIONS: This is the largest reported single-center experience of pLTx with substantial follow-up time and a large re-pLTx experience. Important transplant predictors of graft survival include weight, renal function, modern era, warm ischemia time, and time between primary transplantation and re-pLTx. Renal function, mechanical ventilation, and underlying cause of liver disease affect patient survival. Awareness of these factors can help in the decision making for children requiring pLTx.
Authors: Micaela Raices; Matias Eduardo Czerwonko; Victoria Ardiles; Gustavo Boldrini; Daniel D'Agostino; José Marcó Del Pont; Juan Pekolj; Juan Mattera; Claudio Brandi; Miguel Ciardullo; Eduardo de Santibañes; Martin de Santibañes Journal: J Gastrointest Surg Date: 2019-03-18 Impact factor: 3.452
Authors: Emad Hamdy Gad; Ahmed Nabil Sallam; Hosam Soliman; Tarek Ibrahim; Tahany Abdel Hameed Salem; Mohammed Abdel-Hafez Ali; Mohammed Al-Sayed Abd-Same; Islam Ayoub Journal: Ann Med Surg (Lond) Date: 2022-06-07
Authors: Dmitri Bezinover; Lauren Nahouraii; Alexandr Sviatchenko; Ming Wang; Steven Kimatian; Fuat H Saner; Jonathan G Stine Journal: Transplant Direct Date: 2020-09-17
Authors: Ioannis A Ziogas; W Kelly Wu; Lea K Matsuoka; Anita K Pai; Einar T Hafberg; Lynette A Gillis; Thomas M Morgan; Sophoclis P Alexopoulos Journal: Liver Transpl Date: 2021-08-01 Impact factor: 6.112
Authors: Mohit Kehar; Rulan S Parekh; Jennifer Stunguris; Maria De Angelis; Krista Van Roestel; Anand Ghanekar; Mark Cattral; Annie Fecteau; Simon Ling; Binita M Kamath; Nicola Jones; Yaron Avitzur; David Grant; Vicky Lee Ng Journal: Transplant Direct Date: 2019-02-27
Authors: Simon Moosburner; Leke Wiering; Safak Gül-Klein; Paul Ritschl; Tomasz Dziodzio; Nathanael Raschzok; Christian Witzel; Alexander Gratopp; Stephan Henning; Philip Bufler; Moritz Schmelzle; Georg Lurje; Wenzel Schöning; Johann Pratschke; Brigitta Globke; Robert Öllinger Journal: J Clin Med Date: 2022-02-09 Impact factor: 4.241
Authors: Benas Prusinskas; Sinja Ohlsson; Simone Kathemann; Denisa Pilic; Kristina Kampmann; Rainer Büscher; Andreas Paul; Lars Pape; Peter F Hoyer; Elke Lainka Journal: Front Pediatr Date: 2021-06-02 Impact factor: 3.418
Authors: Martha M Ruiz; Rashid Alobaidi; Michelle Lisa Noga; Robin Featherstone; James Shapiro; Ravi Bhargava Journal: BMJ Open Date: 2019-12-10 Impact factor: 2.692
Authors: Cristina M Farkas-Skiles; Robert B Ettenger; Jonathan E Zuckerman; Meghan Pearl; Robert S Venick; Patricia L Weng Journal: Pediatr Nephrol Date: 2021-07-22 Impact factor: 3.714